# Long-term Pre-dialysis Extension in Europe and Asia Pacific

Study · id `cardio:ct-nct02055482` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02055482](<https://clinicaltrials.gov/study/NCT02055482>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02055482

Browse, organ or system: Kidneys  
Browse, condition area: Kidney connections  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 166 participants.

## Technical summary

Registry record NCT02055482. Randomized; no masking; primary purpose treatment. Start 2014-06-24 (actual); primary completion 2016-11-15 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 166 participants (enrolled count; ClinicalTrials.gov record NCT02055482, source copy `cardio:ctgov-nct02055482-2017-11-22`, retrieved 2026-10-26)
- Started: 2014-06-24 (actual) (ClinicalTrials.gov record NCT02055482, source copy `cardio:ctgov-nct02055482-2017-11-22`, retrieved 2026-10-26)
- Primary completion: 2016-11-15 (actual) (ClinicalTrials.gov record NCT02055482, source copy `cardio:ctgov-nct02055482-2017-11-22`, retrieved 2026-10-26)
- Completion: 2016-12-12 (actual) (ClinicalTrials.gov record NCT02055482, source copy `cardio:ctgov-nct02055482-2017-11-22`, retrieved 2026-10-26)
- Countries: Australia; Bulgaria; France; Germany; Hungary; Israel; Italy; Japan; Poland; Romania; South Korea; Spain; Türkiye; United Kingdom (ClinicalTrials.gov record NCT02055482, source copy `cardio:ctgov-nct02055482-2017-11-22`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02055482-2017-11-22`, retrieved 2026-10-26)

## The registry's words

- Brief title: Long-term Pre-dialysis Extension in Europe and Asia Pacific
- Acronym: DIALOGUE 3
- Condition: Anemia
- Condition: Renal Insufficiency, Chronic
- Intervention (Drug): Molidustat (BAY85-3934)
- Intervention (Biological): Darbepoetin
- Lead sponsor: Bayer
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Chronic kidney disease (CKD) (`cardio:chronic-kidney-disease`)
- Registry lists this organization as the lead sponsor: Bayer (`cardio:bayer`)

## Provenance

Content hash: 09c2ecf01f4be23966d474e10251cf5fbf2bd15c4719323f40f8ff6bf9465f57
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
